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The fi  ndings of the California Teachers Study
Th   e report from the California Teachers Study cohort [1] 
in this issue of Breast Cancer Research adds to the 
mounting evidence that reductions in the use of meno-
pausal hormone therapy (HT) are largely responsible for 
the recent declines in breast cancer that have been 
observed in many countries in women 50 years old or 
older [2-4]. Th  e study followed 74,647 female teachers 
and administrators from public schools; the women 
included in this analysis were 50 years old or older and 
were recruited to the study in 1995-1996 [1]. A total of 
2,668 incident invasive and 565 in situ breast cancers 
were diagnosed in the cohort [1]. Th   e prevalence of HT 
use at baseline was extremely high, with around 60% of 
women reporting current use. HT use was updated in 
2000-2001, with illustrative data in 2005-2006 available 
for a subset of the cohort.
Th  e investigators found a 26% reduction in invasive 
breast cancer in the cohort from 2000-2002 to 2003-2005 
[1]. Th   is accompanied an   estimated 64% drop in HT use 
between 2000-2001 (58% current HT use) and 2005-2006 
(21% current HT use) following publication of the main 
results of the Women’s Health Initiative (WHI) trial [1,5]. 
By collating individual data on the use of HT and breast 
cancer incidence, they demonstrated that the decline in 
incidence was concentrated in women who had ceased 
HT use. Th   e decline was greater in prior users of oestrogen-
progestagen HT (47% decline; P < 0.001) than in oestrogen-
only HT (26% decline; P = 0.01) but was substantial and 
signiﬁ   cant in both groups and reﬂ   ected a decrease 
predominantly in oestrogen receptor-positive tumours 
[1]. Almost 97% of the cohort reported mammographic 
screening according to recommended guidelines, and 
rates of in situ cancers remained stable, indicating 
consistent screening patterns over the period [1].
The plausibility of a rapid drop in breast cancer 
incidence following cessation of use of menopausal 
hormone therapy
It is now clear that breast cancer risk is elevated in 
women using HT [6]; ecological [2,3] and observational 
[7,8] studies show that this elevated risk declines rapidly 
following cessation of use. Th  e follow-up data from the 
California Teachers Study cohort build on the recently 
published analyses of the WHI trial and its associated 
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© 2010 BioMed Central Ltdobservational cohort study [9]. Th  ese analyses demon-
strated rapid reductions in breast cancer incidence 
follow  ing cessation of combined HT; in the WHI obser-
vational cohort, breast cancer incidence declined by 43% 
from 2002 to 2003 in women who had ceased use of HRT 
[9]. Because these cohort studies were large enough to 
identify statistically signiﬁ   cant falls in breast cancer 
incidence from 2002 onwards, they conﬁ  rm the ecological 
studies’ ﬁ  ndings [1,9]; and because both studies collated 
individual-level information on HT use, they have 
additionally conﬁ  rmed that the declines in breast cancer 
occurred in women who had ceased HT [1,9].
Th  e greater breast cancer decline in former users of 
oestrogen-progestagen versus oestrogen-only HT observed 
in the California Teachers Study is consistent with prior 
data on the magnitude of the risks associated with each 
[6,8]; and the fact that the decline was observed 
predominantly in oestrogen receptor-positive tumours is 
consistent with the emerging evidence that HT par-
ticularly increases the risk of oestrogen receptor-positive 
breast cancer [10,11]. Furthermore, the rapidity of the 
decline in breast cancer with HT cessation is in keeping 
with the historical precedents of declining endometrial 
cancer following reductions in oestrogen-only HT in the 
1970s [12] and rapid reductions in lung cancer risk 
following smoking cessation [13].
Current drug regulations and patterns of use
Th   ere is broad consensus in the guidance issued by drug 
regulatory authorities in the UK, US, Europe and 
Australia in recommending that HT be used only for 
treatment of moderate to severe menopausal symptoms, 
for as short a time as possible, and not generally for the 
ﬁ   rst-line prevention of osteoporosis or other chronic 
disease [14].
Th   e risks of use of HT, particularly prolonged use, are 
not trivial. Th  e most recent independent quantitative 
review of the evidence ﬁ   nds that 5 years of use of 
combined HT among women in their ﬁ  fties leads to the 
development of an excess potentially life-threatening 
condition attributable to HT among 1.4% of users; that is, 
net excess cases of breast cancer, stroke, ovarian cancer, 
endometrial cancer or venous thromboembolism that are 
not oﬀ  set by reduced hip fracture or colorectal cancer 
incidence (number needed to harm = 71) [6]. Th   is rises to 
4.0% (number needed to harm = 25) with 10 years of use. 
Th   e corresponding ﬁ  gures for oestrogen-only HT use in 
women in their ﬁ   fties without a uterus are 0.5% for 
5 years of use and 1.2% for 10 years of use [6]. Th  e  overall 
absolute risks related to HT are dependent on whether an 
oestrogen-progestagen or oestrogen-only preparation is 
used, the duration of use, a woman’s age and body mass 
index and her background risk of the relevant conditions. 
Th   e most comprehensive analyses to date do not support 
the ‘timing hypothesis’; hence, the relative risks and 
beneﬁ   ts are not inﬂ  uenced  signiﬁ   cantly by the time 
between menopause and commencing use [15].
In keeping with other US ﬁ  ndings [2], the reduction in 
HT use in the California Teachers Study cohort from 
2002 onwards was dramatic. Population-wide reductions 
in breast cancer have been widely attributed to more 
cautious and targeted use of HT [4]. Yet 21% of the 
California Teachers Study cohort were current HT users 
in the 2005-2006 resurvey, highlighting the fact that large 
numbers of women continue to use HT. Th  e optimal 
prevalence of HT is not known. However, use should 
predominantly be short-term and should reﬂ  ect both the 
prevalence of moderate to severe menopausal symptoms 
and the proportion of well-informed women who choose 
to use HT as treatment for these symptoms after due 
consideration of its risks and beneﬁ  ts.
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